Evidence map›Paper›PMID 21530210›Full record

ArticleProstaglandins, leukotrienes, and essential fatty acids2011

Time-dependent changes in the brain arachidonic acid cascade during cuprizone-induced demyelination and remyelination.

S Palumbo, C D Toscano, L Parente, R Weigert, F Bosetti

Open access · greenAbstract read
In one paragraph

Article in Prostaglandins, leukotrienes, and essential fatty acids, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Astrocytes: Lessons Learned from the Cuprizone Model.International journal of molecular sciences · 2023
    Review
  3. Review
  4. Article
  5. Article
  6. Preventive Effect ofInternational journal of preventive medicine · 2020
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Flavonolignans inhibit the arachidonic acid pathway in blood platelets.BMC complementary and alternative medicine · 2017
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Tissue-specific differences in brain phosphodiesters in late-life major depression.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2014
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

S PalumboNational Institute on Aging, National Institutes of Health, Brain Physiology and Metabolism Section, Bethesda, MD 20892-0947, USA.
C D Toscano
L Parente
R Weigert
F Bosetti
National Institutes of Health · USNational Institute of Dental and Craniofacial Research · US

Funding

Molecular Mechanisms regulating membrane trafficking in salivary glandsZIADE000717 · NIDCR · NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH · PI WEIGERT, ROBERTO · 2009 to 2015
$9.2M
Brain arachidonic acid metabolism in primary demyelination and remyelinationZIAAG000430 · NIA · NATIONAL INSTITUTE ON AGING · PI BOSETTI, FRANCESCA · 2009 to 2010
$833k
Intramural NIH HHS ZIA AG000430
6 · The paper itself

Abstract

Phospholipases A(2) (PLA(2)) are the enzymatic keys for the activation of the arachidonic acid (AA) cascade and the subsequent synthesis of pro-inflammatory prostanoids (prostaglandins and tromboxanes). Prostanoids play critical roles in the initiation and modulation of inflammation and their levels have been reported increased in several neurological and neurodegenerative disorders, including multiple sclerosis (MS). Here, we aimed to determine whether brain expression PLA(2) enzymes and the terminal prostagland in levels are changed during cuprizone-induced demyelination and in the subsequent remyelination phase. Mice were given the neurotoxicant cuprizone through the diet for six weeks to induce brain demyelination. Then, cuprizone was withdrawn and mice were returned to a normal diet for 6 weeks to allow spontaneous remyelination. We found that after 4-6 weeks of cuprizone, sPLA(2)(V) and cPLA(2), but not iPLA(2)(VI), gene expression was upregulated in the cortex, concomitant with an increase in the expression of astrocyte and microglia markers. Cyclooxygenase (COX)-2 gene expression was consistently upregulated during all the demyelination period, whereas COX-1 sporadically increased only at week 5 of cuprizone exposure. However, we found that at the protein level only sPLA(2)(V) and COX-1 were elevated during demyelination, with COX-1 selectively expressed by activated and infiltrated microglia/macrophages and astrocytes. Levels of PGE(2), PGD(2), PGI(2) and TXB(2) were also increased during demyelination. During remyelination, none of the PLA(2) isoforms was significantly changed, whereas COX-1 and -2 were sporadically upregulated only at the gene expression level. PGE(2), PGI(2) and PGD(2) levels returned to normal, whereas TXB(2) was still upregulated after 3 weeks of cuprizone withdrawal. Our study characterizes for the first time time-dependent changes in the AA metabolic pathway during cuprizone-induced demyelination and the subsequent remyelination and suggests that sPLA(2)(V) is the major isoform contributing to AA release.

Indexed as

AnimalsArachidonic AcidsAstrocytesCerebral CortexCuprizoneCyclooxygenase 1Cyclooxygenase 2Demyelinating DiseasesGene Expression Regulation, EnzymologicGroup V Phospholipases A2MacrophagesMaleMembrane ProteinsMiceMice, Inbred C57BLMicrogliaArachidonic AcidsCuprizoneCyclooxygenase 1Cyclooxygenase 2Group V Phospholipases A2Membrane ProteinsNerve Tissue ProteinsPhospholipases A2, CytosolicPla2g5 protein, mousePtgs1 protein, mousePtgs2 protein, mouseRNA, Messenger

Identifiers

PMID21530210
PMCPMC3109126
OpenAlexW2137977438

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.